NCT00109187已完成3 期
Open-Label Extension Study II of Xolair (Omalizumab) in Moderate to Severe, Persistent Asthma Subjects Who Completed Study Q2143g (ALTO)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
研究概览
简要总结
This is a Phase IIIb, multicenter, open-label, extension study available to subjects who successfully complete Study Q2143g and have not participated in Study Q2195g. Subjects should be registered via the IVRS (Interactive Voice Response System) within 48 hours prior to their baseline visit. All subjects in this study will be treated with Xolair for 24 weeks. Subjects in the New Treatment Group may require additional visits for study drug injections (as frequently as every 2 weeks). Data collection during these additional visits will be limited to the assessment of adverse events. The study will evaluate all serious and nonserious adverse events, laboratory assessments, data on asthma exacerbations, and concomitant medication usage.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Successful completion of the 24-week study period in Study Q2143g
- •Signed informed consent (in the case of a minor, consent must be given by the child's parent or legally authorized representative)
- •For subjects who have never received Xolair, a serum IgE level >=30 IU/mL and <=1300 IU/mL and have a body weight >=20 kg and <=150 kg
- •Females of childbearing potential must, in the opinion of the investigator, be using an effective method of contraception to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study.
排除标准
- •Thrombocytopenia as evidenced by a platelet count of <100,000/uL
- •Pregnant or breastfeeding
- •Significant systemic disease (e.g., infection, hematologic, renal, hepatic, coronary heart disease or other cardiovascular diseases, endocrine or gastrointestinal disease) within the previous 3 months
- •History of neoplasia
- •Any systemic condition requiring regular administration of an immunoglobulin
- •Known hypersensitivity to any ingredients of Xolair, including excipients (sucrose, histidine, polysorbate 20)
- •History of noncompliance with medical regimens
- •Current participation in a study using an investigational new drug other than Xolair
- •Participation in Study Q2195g
研究者
相似试验
已完成
2 期
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788gPeanut HypersensitivityNCT00382148Genentech, Inc.11
已完成
2 期
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's DiseaseCrohn's Disease (CD)NCT02782663AbbVie107
已完成
2 期
An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid ArthritisRheumatoid ArthritisNCT02518620Ablynx, a Sanofi company406
终止
2 期
An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT03407482Genentech, Inc.160
终止
2 期
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) StudyUrticariaNCT03693625Genentech, Inc.31